Rituximab and protection from vaccine preventable diseases: applying the evidence to pediatric patients

References

• Crawford NW, Bines JE, Royle J, et al. Optimizing immunization in pediatric special risk groups. Expert Rev Vaccines. 2011;10(2):175–186.
   PubMed Web of Science ®Google Scholar
• Arvas A. Vaccination in patients with immunosuppression. Turk Pediatri Ars. 2014;49(3):181–185.
   PubMedGoogle Scholar
• Akikusa JD, Crawford NW. Vaccination in paediatric rheumatology. Curr Rheumatol Rep. 2014;16(8):432.
   PubMed Web of Science ®Google Scholar
• Morin MP, Quach C, Fortin E, et al. Vaccination coverage in children with juvenile idiopathic arthritis followed at a paediatric tertiary care centre. Rheumatol (Oxford). 2012;51(11):2046–2050.
   PubMed Web of Science ®Google Scholar
• Moulis G, Lapeyre-Mestre M, Mahevas M, et al. Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France. Am J Hematol. 2015;90(4):301–305.
   PubMed Web of Science ®Google Scholar
• Heijstek MW, Ott de Bruin LM, Bijl M, et al. EULAR recommendations for vaccination in paediatric patients with rheumatic diseases. Ann Rheum Dis. 2011;70(10):1704–1712.
   PubMed Web of Science ®Google Scholar
• Cooper N, Bussel JB. The long-term impact of rituximab for childhood immune thrombocytopenia. Curr Rheumatol Rep. 2010;12(2):94–100.
   PubMedGoogle Scholar
• Dai WJ, Zhang RR, Yang XC, et al. Efficacy of standard dose rituximab for refractory idiopathic thrombocytopenic purpura in children. Eur Rev Med Pharmacol Sci. 2015;19(13):2379–2383.
   PubMed Web of Science ®Google Scholar
• Minard-Colin V, Brugières L, Reiter A, et al. Non-Hodgkin lymphoma in children and adolescents: progress through effective collaboration, current knowledge, and challenges ahead. J Clin Oncol. 2015;33(27):2963–2974.
   PubMed Web of Science ®Google Scholar
• Ravani P, Rossi R, Bonanni A, et al. Rituximab in children with steroid-dependent nephrotic syndrome: A multicenter, open-label, noninferiority, randomized controlled trial. J Am Soc Nephrol. 2015;26(9):2259–2266.
   PubMed Web of Science ®Google Scholar
• Tambralli A, Beukelman T, Cron RQ, et al. Safety and efficacy of rituximab in childhood-onset systemic lupus erythematosus and other rheumatic diseases. J Rheumatol. 2015;42(3):541–546.
   PubMed Web of Science ®Google Scholar
• Webb H, Jaureguiberry G, Dufek S, et al. Cyclophosphamide and rituximab in frequently relapsing/steroid-dependent nephrotic syndrome. Pediatr Nephrol. 2015;31(4):589–594.
   PubMed Web of Science ®Google Scholar
• Salzer J, Lycke J, Wickström R, et al. Rituximab in paediatric onset multiple sclerosis: a case series. J Neurol. 2016;263(2):322–326.
   PubMed Web of Science ®Google Scholar
• Choi PY, Roncolato F, Badoux X, et al. A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4). Blood. 2015;126(4):500–503.
   PubMed Web of Science ®Google Scholar
• van der Kolk LE, Baars JW, Prins MH, et al. Rituximab treatment results in impaired secondary humoral immune responsiveness. Blood. 2002;100(6):2257–2259.
   PubMed Web of Science ®Google Scholar
• Vallerskog T, Gunnarsson I, Widhe M, et al. Treatment with rituximab affects both the cellular and the humoral arm of the immune system in patients with SLE. Clin Immunol (Orlando, Fla). 2007;122(1):62–74.
   PubMed Web of Science ®Google Scholar
• Bingham CO 3rd, Looney RJ, Deodhar A, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial. Arthritis Rheum. 2010;62(1):64–74.
   PubMed Web of Science ®Google Scholar
• Leandro MJ, Cambridge G, Ehrenstein MR, et al. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. Arthritis Rheum. 2006;54(2):613–620.
   PubMed Web of Science ®Google Scholar
• Nakou M, Katsikas G, Sidiropoulos P, et al. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. Arthritis Res Ther. 2009;11(4):R131.
   PubMed Web of Science ®Google Scholar
• Buch MH, Smolen JS, Betteridge N, et al. Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(6):909–920.
   PubMed Web of Science ®Google Scholar
• Rehnberg M, Amu S, Tarkowski A, et al. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. Arthritis Res Ther. 2009;11(4):R123.
   PubMed Web of Science ®Google Scholar
• Cioc AM, Vanderwerf SM, Peterson BA, et al. Rituximab-induced changes in hematolymphoid tissues found at autopsy. Am J Clin Pathol. 2008;130(4):604–612.
   PubMed Web of Science ®Google Scholar
• Thurlings RM, Vos K, Wijbrandts CA, et al. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. Ann Rheum Dis. 2008;67(7):917–925.
   PubMed Web of Science ®Google Scholar
• Vos K, Thurlings RM, Wijbrandts CA, et al. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum. 2007;56(3):772–778.
   PubMed Web of Science ®Google Scholar
• Bennett CM, Rogers ZR, Kinnamon DD, et al. Prospective phase 1/2 study of rituximab in childhood and adolescent chronic immune thrombocytopenic purpura. Blood. 2006;107(7):2639–2642.
   PubMed Web of Science ®Google Scholar
• Wang J, Wiley JM, Luddy R, et al. Chronic immune thrombocytopenic purpura in children: assessment of rituximab treatment. J Pediatr. 2005;146(2):217–221.
   PubMed Web of Science ®Google Scholar
• Taube T, Schmid H, Reinhard H, et al. Effect of a single dose of rituximab in chronic immune thrombocytopenic purpura in childhood. Haematologica. 2005;90(2):281–283.
   PubMed Web of Science ®Google Scholar
• Oren S, Mandelboim M, Braun-Moscovici Y, et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis. 2008;67(7):937–941.
   PubMed Web of Science ®Google Scholar
• Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum. 2006;54(9):2793–2806.
   PubMed Web of Science ®Google Scholar
• Keystone E, Fleischmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. Arthritis Rheum. 2007;56(12):3896–3908.
   PubMed Web of Science ®Google Scholar
• Bisogno G. Persistent B-cell depletion after rituximab for thrombocytopenic purpura. Eur J Pediatr. 2007;166(1):85–86.
   PubMed Web of Science ®Google Scholar
• Gluck T, Muller-Ladner U. Vaccination in patients with chronic rheumatic or autoimmune diseases. Clin Infect Dis off Publ Infect Dis Soc Am. 2008;46(9):1459–1465.
   PubMed Web of Science ®Google Scholar
• Rao A, Kelly M, Musselman M, et al. Safety, efficacy, and immune reconstitution after rituximab therapy in pediatric patients with chronic or refractory hematologic autoimmune cytopenias. Pediatr Blood Cancer. 2008;50(4):822–825.
   PubMed Web of Science ®Google Scholar
• Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med. 2004;350(25):2572–2581.
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Emery P, Bingham CO 3rd, et al. Long-term safety of patients receiving rituximab in rheumatoid arthritis clinical trials. J Rheumatol. 2010;37(3):558–567.
   PubMed Web of Science ®Google Scholar
• Wilk E, Witte T, Marquardt N, et al. Depletion of functionally active CD20+ T cells by rituximab treatment. Arthritis Rheum. 2009;60(12):3563–3571.
   PubMed Web of Science ®Google Scholar
• Stroopinsky D, Katz T, Rowe JM, et al. Rituximab-induced direct inhibition of T-cell activation. Cancer Immunol Immunother. 2012;61(8):1233–1241.
   PubMed Web of Science ®Google Scholar
• Melet J, Mulleman D, Goupille P, et al. Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response. Arthritis Rheum. 2013;65(11):2783–2790.
   PubMed Web of Science ®Google Scholar
• Piantoni S, Scarsi M, Tincani A, et al. Circulating CD4+ T-cell number decreases in rheumatoid patients with clinical response to rituximab. Rheumatol Int. 2015;35(9):1571–1573.
   PubMed Web of Science ®Google Scholar
• Nazi I, Kelton JG, Larche M, et al. The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood. 2013;122(11):1946–1953.
   PubMed Web of Science ®Google Scholar
• Cho CH, Hwang WL, Cheng SB, et al. Hepatitis B reactivation induced by Rituximab maintenance therapy for lymphoma. Ann Hematol. 2011;90(1):111–112.
   PubMed Web of Science ®Google Scholar
• Liang R. How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation. Blood. 2009;113(14):3147–3153.
   PubMed Web of Science ®Google Scholar
• Pei SN, Chen CH, Lee CM, et al. Reactivation of hepatitis B virus following rituximab-based regimens: a serious complication in both HBsAg-positive and HBsAg-negative patients. Ann Hematol. 2010;89(3):255–262.
   PubMed Web of Science ®Google Scholar
• Tsutsumi Y, Yamamoto Y, Ito S, et al. Hepatitis B virus reactivation with a rituximab-containing regimen. World J Hepatol. 2015;7(21):2344–2351.
   PubMed Web of Science ®Google Scholar
• Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the research on adverse drug events and reports project. Blood. 2009;113(20):4834–4840.
   PubMed Web of Science ®Google Scholar
• Xanthouli P, Sailer S, Fiehn C. Rituximab (RTX) as an alternative to TNF-Alpha antagonists in patients with rheumatoid arthritis and high risk of severe infections: a systematic analysis of the experience in one center. Open Rheumatol J. 2012;6:286–289.
   PubMedGoogle Scholar
• Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007;146(1):25–33.
   PubMed Web of Science ®Google Scholar
• Streif W, Escuriola Ettingshausen C, Linde R, et al. Inhibitor treatment by rituximab in congenital haemophilia A - Two case reports. Hamostaseologie. 2009;29(2):151–154.
   PubMedGoogle Scholar
• Quartier P, Tournilhac O, Archimbaud C, et al. Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment. Clin Infect Dis off Publ Infect Dis Soc Am. 2003;36(3):e47–e49.
   PubMed Web of Science ®Google Scholar
• Ng PC, Lee KK, Lo AF, et al. Anti B cell targeted immunotherapy for treatment of refractory autoimmune haemolytic anaemia in a young infant. Arch Dis Child. 2003;88(4):337–339.
   PubMed Web of Science ®Google Scholar
• Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17(7):1055–1065.
   PubMed Web of Science ®Google Scholar
• Westra J, Rondaan C, van Assen S, et al. Vaccination of patients with autoimmune inflammatory rheumatic diseases. Nat Rev Rheumatol. 2015;11(3):135–145.
   PubMed Web of Science ®Google Scholar
• Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev. 2005;31(6):456–473.
   PubMed Web of Science ®Google Scholar
• Hua C, Barnetche T, Combe B, et al. Effect of methotrexate, anti-tumor necrosis factor alpha, and rituximab on the immune response to influenza and pneumococcal vaccines in patients with rheumatoid arthritis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2014;66(7):1016–1026.
   PubMed Web of Science ®Google Scholar
• Arad U, Tzadok S, Amir S, et al. The cellular immune response to influenza vaccination is preserved in rheumatoid arthritis patients treated with rituximab. Vaccine. 2011;29(8):1643–1648.
   PubMed Web of Science ®Google Scholar
• Bedognetti D, Zoppoli G, Massucco C, et al. Impaired response to influenza vaccine associated with persistent memory B cell depletion in non-Hodgkin’s lymphoma patients treated with rituximab-containing regimens. J Immunol (Baltimore, Md: 1950). 2011;186(10):6044–6055.
   PubMed Web of Science ®Google Scholar
• Eisenberg RA, Jawad AF, Boyer J, et al. Rituximab-treated patients have a poor response to influenza vaccination. J Clin Immunol. 2013;33(2):388–396.
   PubMed Web of Science ®Google Scholar
• Gelinck LB, Teng YK, Rimmelzwaan GF, et al. Poor serological responses upon influenza vaccination in patients with rheumatoid arthritis treated with rituximab. Ann Rheum Dis. 2007;66(10):1402–1403.
   PubMed Web of Science ®Google Scholar
• Kapetanovic MC, Kristensen LE, Saxne T, et al. Impact of anti-rheumatic treatment on immunogenicity of pandemic H1N1 influenza vaccine in patients with arthritis. Arthritis Res Ther. 2014;16(1):R2.
   PubMed Web of Science ®Google Scholar
• Kim W, Kim SH, Huh SY, et al. Reduced antibody formation after influenza vaccination in patients with neuromyelitis optica spectrum disorder treated with rituximab. Eur J Neurol. 2013;20(6):975–980.
   PubMed Web of Science ®Google Scholar
• Rehnberg M, Brisslert M, Amu S, et al. Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment. Arthritis Res Ther. 2010;12(3):R111.
   PubMed Web of Science ®Google Scholar
• van Assen S, Holvast A, Benne CA, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. Arthritis Rheum. 2010;62(1):75–81.
   PubMed Web of Science ®Google Scholar
• Westra J, van Assen S, Wilting KR, et al. Rituximab impairs immunoglobulin (Ig)M and IgG (subclass) responses after influenza vaccination in rheumatoid arthritis patients. Clin Exp Immunol. 2014;178(1):40–47.
   PubMed Web of Science ®Google Scholar
• Yri OE, Torfoss D, Hungnes O, et al. Rituximab blocks protective serologic response to influenza A (H1N1) 2009 vaccination in lymphoma patients during or within 6 months after treatment. Blood. 2011;118(26):6769–6771.
   PubMed Web of Science ®Google Scholar
• Crnkic Kapetanovic M, Saxne T, Jonsson G, et al. Rituximab and abatacept but not tocilizumab impair antibody response to pneumococcal conjugate vaccine in patients with rheumatoid arthritis. Arthritis Res Ther. 2013;15(5):R171.
   PubMed Web of Science ®Google Scholar
• Albert D, Dunham J, Khan S, et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis. 2008;67(12):1724–1731.
   PubMed Web of Science ®Google Scholar
• Berglund A, Willen L, Grodeberg L, et al. The response to vaccination against influenza A(H1N1) 2009, seasonal influenza and streptococcus pneumoniae in adult outpatients with ongoing treatment for cancer with and without rituximab. Acta Oncol. 2014;53(9):1212–1220.
   PubMed Web of Science ®Google Scholar
• Horwitz SM, Negrin RS, Blume KG, et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood. 2004;103(3):777–783.
   PubMed Web of Science ®Google Scholar
• Withers DR, Fiorini C, Fischer RT, et al. T cell-dependent survival of CD20+ and CD20- plasma cells in human secondary lymphoid tissue. Blood. 2007;109(11):4856–4864.
   PubMed Web of Science ®Google Scholar
• MacIntyre R, Stein A, Harrison C, et al. Increasing trends of herpes zoster in Australia. PLoS One. 2015;10(4):e0125025.
   PubMed Web of Science ®Google Scholar
• Bearden CM, Agarwal A, Book BK, et al. Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174. Am J Transpl Offi J Am Soc Transpl Am Soc Transpl Surg. 2005;5(1):50–57.
   Web of Science ®Google Scholar
• National Institutes of Health. Clinicaltrials.gov - Search Results 2016 Available from: https://clinicaltrials.gov/ct2/results?term=rituximab+vaccine&recr=&rslt=&type=&cond=&intr=&titles=&outc=&spons=&lead=&id=&state1=&cntry1=&state2=&cntry2=&state3=&cntry3=&locn=&gndr=&age=0&rcv_s=&rcv_e=&lup_s=&lup_e=.
   Google Scholar
• Heijstek MW, van Gageldonk PG, Berbers GA, et al. Differences in persistence of measles, mumps, rubella, diphtheria and tetanus antibodies between children with rheumatic disease and healthy controls: a retrospective cross-sectional study. Ann Rheum Dis. 2012;71(6):948–954.
   PubMed Web of Science ®Google Scholar
• National Health and Medical Research Council (NHMRC). Australian Immuniation Handbook - Vaccination for Special Risk Groups 2014 [10th edition. Available from: http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home~handbook10part3.
   Google Scholar
• National Health and Medical Research Council (NHMRC) Australian Immunization Handbook - Q Fever 2014. Available from: http://www.immunise.health.gov.au/internet/immunise/publishing.nsf/Content/Handbook10-home~handbook10part4~handbook10-4-15.
   Google Scholar
• Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med. 2009;361(22):2143–2152.
   PubMed Web of Science ®Google Scholar
• Cambridge G, Leandro MJ, Teodorescu M, et al. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum. 2006;54(11):3612–3622.
   PubMed Web of Science ®Google Scholar
• Papadopoulou D, Sipsas NV. Comparison of national clinical practice guidelines and recommendations on vaccination of adult patients with autoimmune rheumatic diseases. Rheumatol Int. 2014;34(2):151–163.
   PubMed Web of Science ®Google Scholar
• Kobayashi I, Mori M, Yamaguchi K, et al. Pediatric rheumatology association of Japan recommendation for vaccination in pediatric rheumatic diseases. Mod Rheumatol. 2015;25(3):335–343.
   PubMed Web of Science ®Google Scholar
• Mori S, Fujiyama S. Hepatitis B virus reactivation associated with antirheumatic therapy: risk and prophylaxis recommendations. World J Gastroenterol. 2015;21(36):10274–10289.
   PubMed Web of Science ®Google Scholar
• Mok CC. Rituximab for the treatment of rheumatoid arthritis: an update. Drug Des Devel Ther. 2014;8:87–100.
   Web of Science ®Google Scholar
• Burr ML, Malaviya AP, Gaston JH, et al. Rituximab in rheumatoid arthritis following anti-TNF-associated tuberculosis. Rheumatol (Oxford). 2008;47(5):738–739.
   PubMed Web of Science ®Google Scholar
• Jung N, Owczarczyk K, Hellmann M, et al. Efficacy and safety of rituximab in a patient with active rheumatoid arthritis and chronic disseminated pulmonary aspergillosis and history of tuberculosis. Rheumatol (Oxford). 2008;47(6):932–933.
   PubMed Web of Science ®Google Scholar
• Pehlivan Y, Kisacik B, Bosnak VK, et al. Rituximab seems to be a safer alternative in patients with active rheumatoid arthritis with tuberculosis. BMJ Case Rep. 2013;2013:pii:bcr2012006585. doi: 10.1136/bcr-2012-006585. [Epub ahead of print]
   Google Scholar
• Sidner RA, Book BK, Agarwal A, et al. In vivo human B-cell subset recovery after in vivo depletion with rituximab, anti-human CD20 monoclonal antibody. Hum Antibodies. 2004;13(3):55–62.
   PubMedGoogle Scholar
• St. Clair EW. Good and bad memories following rituximab therapy. Arthritis Rheum. 2010;62(1):1–5.
   PubMed Web of Science ®Google Scholar
• Crawford NW, Heath JA, Ashley D, et al. Survivors of childhood cancer: an Australian audit of vaccination status after treatment. Pediatr Blood Cancer. 2010;54(1):128–133.
   PubMed Web of Science ®Google Scholar
• Compagno N, Cinetto F, Semenzato G, et al. Subcutaneous immunoglobulin in lymphoproliferative disorders and rituximab-related secondary hypogammaglobulinemia: a single-center experience in 61 patients. Haematologica. 2014;99(6):1101–1106.
   PubMed Web of Science ®Google Scholar